As seen on:
As seen on:
Latest Articles
A dividend yield above 5% can beat inflation, but only when payouts are backed by strong cash flow, resilient businesses, and sustainable fundamentals.
A 72.9% market share, a 70% payout ratio, and S$21.7 million in net cash – this unassuming Singapore stock has the makings of a retirement income compounder.
Discover how Microsoft will be able to stay ahead amidst the AI revolution.
Blue chips might be boring to some investors, but they provide income and stability to your portfolio.
As interest rates ease and income investing regains appeal, these four Singapore REITs stand out for their resilience, balance-sheet strength, and ability to deliver sustainable distributions into 2026.
For one thing, putting money into firms in the sector would ensure that they are around when we need them.
Popular
High dividend yields catch your eye for all the right reasons. But what looks like a generous payout today may be a warning sign of trouble tomorrow.
Singapore’s engineering giants saw mixed fortunes while US tech rallied on strong AI spending, highlighting the week’s key market developments from writedowns to record orders and earnings strength.
Want to grow your dividend income? Consider these five stocks.
These four names are poised to benefit from Singapore’s S$5 billion market-boosting plan that could lift investor interest in quality REITs.
Stocks
Some AI-linked stocks have undergone deep selloffs. Before writing them off, investors should ask whether these market selloffs by the market are truly justified by the companies’ fundamentals.
Are Singapore’s retail REITs still a buy? We dive into the 2026 updates for CICT, FCT, and MPACT to see which offers the best growth and distribution yield.
As the lunar new year approaches, here’s what Singapore investors should look for if they’re hoping for bigger “ang pow” payouts in 2026.
It’s time to pivot.
Getting Started
Will technology stocks remain relevant in the brave new world?
The world faces a different kind of problem aside from the pandemic, but one that can be tackled with pharmaceuticals.
With a potential rocky and unsteady recovery post-COVID-19, here’s how you can locate stocks that will do well.
As enticing and appealing as cash might be, the problem is that there is a cost associated with keeping it.